Table 1.
Clinical characteristics at the time of biopsy and follow-up in 74 patients with IgA nephropathy
| At the time of biopsy | Follow-up | ||
|---|---|---|---|
| Age (years) | 39 (18–78) | Duration of follow-up (months) | 48 (4–120) |
| Female | 24 (32·4) | ||
| Hypertension | 44 (60·3) | ||
| Previous macroscopic haematuria | 27 (38·6) | Treated with RAS blockade (ACEi and ARB) | 64 (95) |
| eGFR (ml/min per 1·73 m2) | 67·5 ± 36·5 | Immunosupression | 16 (24) |
| Stages 1, 2, 3, 4 CKD (KDIGO) | 32 (43), 15 (20), 18 (24) and 9 (12) | 50% decline in renal function | 20 (27) |
| Proteinuria (g/day) | 1·96 (0·17–9·8) | End-stage renal disease (dialysis or transplantation) | 16 (22) |
For quantitative variables, values are expressed as the mean ± standard deviation or the median (interquartile range) as appropriate. For qualitative variables, values are expressed as n (%). Immunosuppression includes prednisone and/or azathioprine and/or cyclophosphamide. RAS = renin-angiotensin system; ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; eGFR = estimated glomerular filtration rate.